Literature DB >> 19125574

Influence of preformed Asp23-Lys28 salt bridge on the conformational fluctuations of monomers and dimers of Abeta peptides with implications for rates of fibril formation.

Govardhan Reddy1, John E Straub, D Thirumalai.   

Abstract

Recent experiments have shown that the congener Abeta(1-40)[D23-K28], in which the side chains of charged residues Asp23 and Lys28 are linked by a lactam bridge, forms amyloid fibrils that are structurally similar to the wild type (WT) Abeta peptide, but at a rate that is nearly 1000 times faster. We used all atom molecular dynamics simulations in explicit water, and two force fields, of the WT dimer, a monomer with the lactam bridge (Abeta(10-35)-lactam[D23-K28]), and the monomer and dimers with harmonically constrained D23-K28 salt bridge (Abeta(10-35)[D23-K28]) to understand the origin of the enhanced fibril rate formation. The simulations show that the assembly competent fibril-like monomer (N*) structure, which is present among the conformations sampled by the isolated monomer, with strand conformations in the residues spanning the N and C termini and a bend involving residues D(23) VGSNKG(29), are populated to a much greater extent in Abeta(10-35)[D23-K28] and Abeta(10-35)-lactam[D23-K28] than in the WT, which has negligible probability of forming N*. The salt bridge in N* of Abeta(10-35)[D23-K28], whose topology is similar to that found in the fibril, is hydrated. The reduction in the free energy barrier to fibril formation in Abeta(10-35)[D23-K28] and in Abeta(10-35)-lactam[D23-K28], compared to the WT, arises largely due to entropic restriction which enables the bend formation. A decrease in the entropy of the unfolded state and the lesser penalty for conformational rearrangement including the formation of the salt bridge in Abeta peptides with D23-K28 constraint results in a reduction in the kinetic barrier in the Abeta(1-40)-lactam[D23-K28] congener compared to the WT. The decrease in the barrier, which is related to the free energy cost of forming a bend, is estimated to be in the range (4-7)k(B)T. Although a number of factors determine the growth of fibrils, the decrease in the free energy barrier, relative to the WT, to N* formation is a major factor in the rate enhancement in the fibril formation of Abeta(1-40)[D23-K28] congener. Qualitatively similar results were obtained using simulations of Abeta(9-40) peptides and various constructs related to the Abeta(10-35) systems that were probed using OPLS and CHARMM force fields. We hypothesize that mutations or other constraints that preferentially enhance the population of the N* species would speed up aggregation rates. Conversely, ligands that lock it in the fibril-like N* structure would prevent amyloid formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125574      PMCID: PMC3098509          DOI: 10.1021/jp808914c

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  45 in total

1.  Energy landscape of a small peptide revealed by dihedral angle principal component analysis.

Authors:  Yuguang Mu; Phuong H Nguyen; Gerhard Stock
Journal:  Proteins       Date:  2005-01-01

2.  Free energy landscape and folding mechanism of a beta-hairpin in explicit water: a replica exchange molecular dynamics study.

Authors:  Phuong H Nguyen; Gerhard Stock; Emil Mittag; Chin-Kun Hu; Mai Suan Li
Journal:  Proteins       Date:  2005-12-01

3.  Folding events in the 21-30 region of amyloid beta-protein (Abeta) studied in silico.

Authors:  Jose M Borreguero; Brigita Urbanc; Noel D Lazo; Sergey V Buldyrev; David B Teplow; H Eugene Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

4.  On the nucleation of amyloid beta-protein monomer folding.

Authors:  Noel D Lazo; Marianne A Grant; Margaret C Condron; Alan C Rigby; David B Teplow
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

5.  Determining the critical nucleus and mechanism of fibril elongation of the Alzheimer's Abeta(1-40) peptide.

Authors:  Nicolas Lux Fawzi; Yuka Okabe; Eng-Hui Yap; Teresa Head-Gordon
Journal:  J Mol Biol       Date:  2006-10-07       Impact factor: 5.469

6.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

7.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

8.  The structure of the Alzheimer amyloid beta 10-35 peptide probed through replica-exchange molecular dynamics simulations in explicit solvent.

Authors:  Andrij Baumketner; Joan-Emma Shea
Journal:  J Mol Biol       Date:  2006-11-10       Impact factor: 5.469

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Stabilities and conformations of Alzheimer's beta -amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects.

Authors:  Buyong Ma; Ruth Nussinov
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

View more
  37 in total

1.  A study of the α-helical intermediate preceding the aggregation of the amino-terminal fragment of the β amyloid peptide (Aβ(1-28)).

Authors:  Ana V Rojas; Adam Liwo; Harold A Scheraga
Journal:  J Phys Chem B       Date:  2011-10-18       Impact factor: 2.991

2.  Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer.

Authors:  Yu-Shan Lin; Gregory R Bowman; Kyle A Beauchamp; Vijay S Pande
Journal:  Biophys J       Date:  2012-01-18       Impact factor: 4.033

Review 3.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

4.  Competition between folding and aggregation in a model for protein solutions.

Authors:  M Maiti; M Rao; S Sastry
Journal:  Eur Phys J E Soft Matter       Date:  2010-06-22       Impact factor: 1.890

5.  Transient β-hairpin formation in α-synuclein monomer revealed by coarse-grained molecular dynamics simulation.

Authors:  Hang Yu; Wei Han; Wen Ma; Klaus Schulten
Journal:  J Chem Phys       Date:  2015-12-28       Impact factor: 3.488

6.  Microsecond molecular dynamics simulation of Aβ42 and identification of a novel dual inhibitor of Aβ42 aggregation and BACE1 activity.

Authors:  Yuan-yuan Wang; Li Li; Tian-tian Chen; Wu-yan Chen; Ye-chun Xu
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

7.  Effect of the Tottori familial disease mutation (D7N) on the monomers and dimers of Aβ40 and Aβ42.

Authors:  Man Hoang Viet; Phuong H Nguyen; Son Tung Ngo; Mai Suan Li; Philippe Derreumaux
Journal:  ACS Chem Neurosci       Date:  2013-09-16       Impact factor: 4.418

8.  Evidence for a partially structured state of the amylin monomer.

Authors:  Sara M Vaiana; Robert B Best; Wai-Ming Yau; William A Eaton; James Hofrichter
Journal:  Biophys J       Date:  2009-12-02       Impact factor: 4.033

9.  Arginine and disordered amyloid-β peptide structures: molecular level insights into the toxicity in Alzheimer's disease.

Authors:  Orkid Coskuner; Olivia Wise-Scira
Journal:  ACS Chem Neurosci       Date:  2013-10-08       Impact factor: 4.418

10.  The structures of the E22Δ mutant-type amyloid-β alloforms and the impact of E22Δ mutation on the structures of the wild-type amyloid-β alloforms.

Authors:  Orkid Coskuner; Olivia Wise-Scira; George Perry; Taizo Kitahara
Journal:  ACS Chem Neurosci       Date:  2012-12-18       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.